Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A
Language English Country United States Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't
PubMed
36054316
DOI
10.1002/ajh.26692
Knihovny.cz E-resources
- MeSH
- Leukemia, Myeloid, Acute * drug therapy MeSH
- Azacitidine * therapeutic use MeSH
- Bridged Bicyclo Compounds, Heterocyclic therapeutic use MeSH
- Humans MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects MeSH
- Sulfonamides therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Azacitidine * MeSH
- Bridged Bicyclo Compounds, Heterocyclic MeSH
- Sulfonamides MeSH
- venetoclax MeSH Browser
AbbVie Inc North Chicago Illinois USA
Aichi Cancer Center Chikusa ku Nagoya Japan
Algemeen Ziekenhuis Sint Jan Brugge Oostende Belgium
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Genentech Inc South San Francisco California USA
Hematology Department of Biomedicine and Prevention University Tor Vergata Rome Italy
Norton Cancer Institute Louisville Kentucky USA
Ruijin Hospital Shanghai China
University Hospital Brno and Masaryk University Brno Czech Republic
See more in PubMed
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.
